DrugMar 22, 2017
Synergy Rx GLYCOLIC ACID 15% LOTION, GLYCOLIC ACID 20% GEL, GLYCOLIC ACID 6% LOTION recall — FDA D-0539-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
Monthly breakdown
2017 recalls by month
Select a month to review the recall records reported during that period.
December 2017183 records · 3 categoriesNovember 2017262 records · 2 categoriesOctober 201750 records · 2 categoriesSeptember 2017124 records · 2 categoriesAugust 2017178 records · 2 categoriesJuly 2017212 records · 2 categoriesJune 2017121 records · 3 categoriesMay 2017245 records · 3 categoriesApril 2017306 records · 2 categoriesMarch 2017226 records · 2 categoriesFebruary 2017106 records · 2 categoriesJanuary 2017396 records · 2 categories
2017 recalls — page 76
Records are ordered by the best available source date.
DrugMar 22, 2017
Synergy Rx VI PEEL recall — FDA D-0578-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
PreviDent 5000 ppm, DRY MOUTH, 1.1% Sodium Fluoride, PRESCRIPTION STRENGTH TOOTHPASTE, SLS recall — FDA D-0521-2017
Label Mix up; rear panel is incorrectly labeled with the PreviDent 5000 Enamel Protect rear panel.
Class IIIFDA: TerminatedColgate Palmolive Co
DrugMar 22, 2017
Synergy Rx 5-FLUOROURACIL IN VANICREAM, FLUOROURACIL in all strengths including 0.05%, 5% recall — FDA D-0527-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx DICLOFENAC 3% and 5% LIP BALM and DICLOFENAC 5% SPF 30 LIP BALM recall — FDA D-0580-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx QUAD PEEL recall — FDA D-0568-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx QUAD BLEACHING CREAM recall — FDA D-0567-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx GENERIC VI PEEL recall — FDA D-0558-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx SUPREME BLEACHING CREAM recall — FDA D-0571-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx TRETINOIN CREAM in all strengths including: 0.1%, 0.05%, TRETINOIN GEL in all recall — FDA D-0588-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx FIRM AND FADE recall — FDA D-0557-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx HCG and HCG with resveratrol Human Chorionic Gonadotropin in different strengths recall — FDA D-0524-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx TRICHLOROACETIC ACID SOLUTION in all strengths including: 10%, 12%, 15 %, 20% recall — FDA D-0544-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Amerisource Health Services GlipiZIDE Extended-release tablets, 2.5 mg, 30-count carton recall — FDA D-0520-2017
Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.
Class IIFDA: TerminatedAmerisource Health Services
DrugMar 22, 2017
Synergy Rx MALEK'S MAGIC recall — FDA D-0563-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Pharmedium Services Buffered Lidocaine, 1%, In Sodium Bicarbonate 8.4%, 1 mL Total Volume in recall — FDA D-0603-2017
Labeling; Label Mixup; outer packaging is incorrectly labeled as Buffered Lidocaine 1% instead of correctly as Buffered Lidocaine 0.9%
Class IIIFDA: TerminatedPharmedium Services, LLC
DrugMar 22, 2017
Synergy Rx DUO Cream recall — FDA D-0556-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
PROTONIX I.V. (pantoprazole sodium) for Injection, Equivalent to 40 mg pantoprazole per recall — FDA D-0516-2017
Subpotent Drug: Out of Specification (OOS) for potency at the 6-month stability time point.
Class IIIFDA: TerminatedPfizer Inc.
DrugMar 22, 2017
Synergy Rx ENHANCED RETIN ANTI-WRINKLE CREAM, ENHANCED RETIN ANTI-WRINKLE CREAM 0.1% recall — FDA D-0583-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx HCG in all strength including: 2,400, 9600,12,000 UNIT POWDER VIAL DROPS, HCG recall — FDA D-0584-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx HYDROQUINONE CREAM in all strengths including 4%, 5%,6%, 7%, 8%, HYDROQUINONE recall — FDA D-0547-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx CLARIFYING CREAM recall — FDA D-0553-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx CLOBETASOL 0.05% IN OLEA BASE, CLOBETASOL 0.05% IN OROBASE, CLOBETASOL 0.05% recall — FDA D-0535-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
G & W Laboratories Clindamycin Phosphate Topical Solution USP, 1% recall — FDA D-0519-2017
CGMP Deviations: an expired active ingredient was used in the manufacture of these recalled lots.
Class IIIFDA: TerminatedG & W Laboratories, Inc.
About the 2017 recall archive
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.